GLP1R in Parkinson's Disease
- Status
- UnknownResults none
- Why it is watched
- non-weight indication: inflammation, parkinsons, neuroinflammation
- Who it enrolls
- age 40 Years to 75 Years; excludes diabetes; no BMI minimum stated; conditions: Parkinson Disease
- Interventions
- Semaglutide
- Conditions
- Parkinson Disease
- Phase and size
- Phase 2 · 120 participants
- Dates
- Start 2019-01-02
Primary completion 2024-12-31 - Sponsor
- Oslo University Hospital (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Motor Function48 months
02Eligibility
Who can take part
Inclusion Criteria: We will include newly diagnosed patients with PD, age 40-75. Diagnosis of clinically established early PD will be made according to the new criteria set by the Movement Disorder Society (Berg D et al Mov Disord 2018). Enrolment must occur within a year from diagnosis. Before inclusion in the trial PD diagnosis must be supported by typical findings on dopamine transporter (DAT)scans. Exclusion Criteria: Patients will be excluded if they have chronic inflammatory brain disorders, as verified or diagnosed on brain magnetic resonance imaging (MRI). Cognitive impairment in PD will be excluded by way of Mini Mental Status (MMS, score \< 25 points) and Montreal Cognitive Assessment (MOCA, score \<25 points). The patients will be excluded if they have diabetes type 2 and cancer, especially if they or family members have familiar medullary thyroid carcinoma, or multiple endocrine neoplastic syndrome type 2 (MEN 2), as well as those having manifest kidney failure (see side effects below). The patients cannot receive long-term treatment with anti-inflammatory drugs, or other experimental drugs. Patients who are pregnant or breastfeeding are excluded.
03Change log
Registry changes
No changes recorded since the trial was added.